GeneTex
United States (US)

FANCL blocking peptide

Cat No. GTX88033-PEP

Application ELISA, Apuri, Blocking
Species Human
APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Dilution
ELISA Assay dependent
Apuri Assay dependent
Blocking Assay dependent
Not tested in other applications.

Specificity/Sensitivity

The peptide was used in the production of GTX88033.
PROPERTIES

Form

Lyophilized powder

Buffer

Lyophilized from 5% (v/v) acetonitrile/H₂O. Reconstitute pellet in 200μl distilled water to obtain a 0.5mg/ml peptide solution.

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

POG blocking peptide , FAAP43 blocking peptide , PHF9 blocking peptide

Background

The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]
Show More +
Package List Price ($)
$ 239